MMP-3 is synthesized as an inactive proenzyme (zymogen) and requires activation to become functionally active. The human recombinant form of MMP-3 is produced in HEK293 cells (Human Embryonic Kidney 293 cells), which are commonly used in biotechnology for the production of recombinant proteins . The recombinant MMP-3 is typically fused with a polyhistidine tag at the C-terminus to facilitate purification .
The active form of MMP-3 can degrade a wide range of ECM components, including proteoglycans, laminin, fibronectin, and collagen . Additionally, MMP-3 can activate other pro-MMPs, such as MMP-1, MMP-7, and MMP-9, thereby amplifying the ECM degradation process .
MMP-3 plays a significant role in various biological processes:
Due to its involvement in various pathological conditions, MMP-3 is a potential therapeutic target for diseases such as arthritis, cardiovascular diseases, and cancer. Inhibitors of MMP-3 are being explored for their potential to modulate ECM degradation and reduce tissue damage in these diseases.
The human recombinant MMP-3 produced in HEK293 cells is purified using proprietary chromatographic techniques to achieve high purity levels (greater than 95% as determined by SDS-PAGE) . The protein is supplied as a sterile filtered colorless solution in a specific formulation to maintain its stability and activity .